Medical Economics
Personalized mRNA Vaccines Slash Melanoma Risk in Late-Stage Trials
A personalized mRNA vaccine for melanoma cuts the risk of cancer returning in late-stage trials, according to recent findings reported across major outlets including NBC News and The Times on Oct. 24, 2026, offering new hope for patients fighting aggressive forms of the disease.